GT Biopharma

Nasdaq has granted GT Biopharma an additional extension until November 16, 2026, to regain compliance with the minimum closing-price requirement of $1.00 per share. To achieve compliance, the stock must close at or above $1.00 for at least ten consecutive trading days; the company meets other listing requirements but has a market capitalization of only about $13.6 million. GT Biopharma is considering measures to restore compliance and meanwhile reported progress in a phase‑1 study of GTB‑5550 and the correction of prior quarterly reports due to an accounting misclassification. » More on de.investing.com

GT Biopharma will restate its quarter-end financials for June 30 and September 30, 2025, after greenshoe stock purchase rights were incorrectly classified as equity instead of liabilities. The correction increases total liabilities by $28.7 million as of June 30, 2025, and resulted in an additional net loss of $28.7 million in the second quarter, bringing the net loss for the period to $30.2 million; a remeasurement of $11.4 million was recorded for the third quarter. The audit committee declared the previously issued quarterly reports unreliable; the corrected reports will be filed with the SEC shortly. » More on de.investing.com

GT Biopharma escalated to cohort 4 (10 µg/kg/day) in the phase‑1 study of TriKE candidate GTB 3650 after six patients in the first three cohorts were treated without reported tolerability issues. Early cohorts showed increased NK‑cell activity, supporting the TriKE platform’s mechanism of action. The company is advancing GTB 5550 for solid tumors in parallel and expects an IND filing in late December 2025 or January 2026. As of Q3 2025 GT Biopharma reported cash of $2.6 million, which is expected to fund operations into early 2026. » More on de.investing.com